Journal of pain and symptom management
-
J Pain Symptom Manage · Feb 2013
Randomized Controlled TrialArmodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial.
Fatigue has been identified in more than one-half of patients with sarcoidosis. Although fatigue is not synonymous with impaired quality of life, most studies of sarcoidosis identify fatigue as a major cause of impaired quality of life. ⋯ Armodafinil treatment led to a significant reduction in fatigue in sarcoidosis patients. This effect was seen even in patients who did not have excessive daytime somnolence.
-
J Pain Symptom Manage · Feb 2013
Randomized Controlled TrialDevelopment of fatigue in cancer survivors: a prospective follow-up study from diagnosis into the year after treatment.
There is a lack of longitudinal studies investigating fatigue from before cancer treatment to long after successful cancer treatment. ⋯ Twenty-two percent of the survivors had severe persistent fatigue in the year after cancer treatment. Fatigue and cognitive behavioral factors predicted persistent fatigue in the year after cancer treatment. Diagnosis or cancer treatment did not predict persistent fatigue. The implication is that cognitive behavioral therapy for postcancer fatigue, aimed at the fatigue-perpetuating factors, could be offered from two months after successful cancer treatment.